1. Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods. (3rd October 2022) Authors: Bonaca, M; Debus, S; Nehler, M; Anand, S; Patel, M; Pap, A F; Deng, H; Hodge, S; Szarek, M; Haskell, L; Muehlhofer, E; Berkowitz, S; Bauersachs, R Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗